sotorasib KRAS G12C
Selected indexed studies
- Sotorasib in KRAS p.G12C-Mutated Advanced Pancreatic Cancer. (N Engl J Med, 2023) [PMID:36546651]
- Sotorasib for Lung Cancers with KRAS p.G12C Mutation. (N Engl J Med, 2021) [PMID:34096690]
- Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C. (N Engl J Med, 2023) [PMID:37870968]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C. (2023) pubmed
- Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRAS(G12C) mutation: a randomised, open-label, phase 3 trial. (2023) pubmed
- Sotorasib in KRAS p.G12C-Mutated Advanced Pancreatic Cancer. (2023) pubmed
- Sotorasib for Lung Cancers with KRAS p.G12C Mutation. (2021) pubmed
- KRAS(G12C) Inhibition with Sotorasib in Advanced Solid Tumors. (2020) pubmed
- Sotorasib with panitumumab in chemotherapy-refractory KRAS(G12C)-mutated colorectal cancer: a phase 1b trial. (2024) pubmed
- Acquired Resistance to KRAS(G12C) Inhibition in Cancer. (2021) pubmed
- KRAS G12C in advanced NSCLC: Prevalence, co-mutations, and testing. (2023) pubmed
- The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. (2019) pubmed
- Sotorasib: A Review in KRAS G12C Mutation-Positive Non-small Cell Lung Cancer. (2022) pubmed